Ignite Creation Date:
2025-12-26 @ 10:57 AM
Ignite Modification Date:
2025-12-29 @ 2:11 PM
Study NCT ID:
NCT04270708
Status:
UNKNOWN
Last Update Posted:
2020-02-17
First Post:
2020-02-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Intranasal Dexmedetomidine vs Oral Triclofos Sodium for EEG in Children With Autism
Sponsor:
Rabin Medical Center
Organization:
Study Overview
Official Title:
Intranasal Dexmedetomidine vs Oral Triclofos Sodium Sedation for Children With Autism Undergoing Electroencephalograms - A Randomized Controlled Trial.
Status:
UNKNOWN
Status Verified Date:
2020-02
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Children with Autistic Spectrum Disorder (ASD) often undergo an Electroencephalography (EEG) as part of routine work up. These children present a challenge to successful EEG execution, due to a lack of co-operation, and thus, are often in need of sedation. Historically we have used orally administered, Triclofos Sodium (TFS) - pharmacologically and physiologically similar to chloral hydrate, for sedation in this age group. However success using this drug is limited to approximately 75% in those aged 5 years and above, and possibly lower in this age group when associated with a diagnosis of ASD. The medication is often poorly tolerated by the oral route, and involves patient agitation, spiting (with incomplete drug ingestion), and immediate vomiting upon administration. Recently we have introduced Intra-nasal Dexmedetomidine (IN DEX), with an initial impression of much improved drug acceptance and possibly improved efficacy over TFS.
We designed this pilot study, with the aim of comparing efficacy, tolerance of drug administration and adverse events between TFS and IN DEX, with the goal of generating initial results as well as feasibility of recruitment for a larger trial.
We designed this pilot study, with the aim of comparing efficacy, tolerance of drug administration and adverse events between TFS and IN DEX, with the goal of generating initial results as well as feasibility of recruitment for a larger trial.
Detailed Description:
Study participants will be allocated, amongst patients invited for routine EEG monitoring in the hospitals EEG facility. All patients will be fasted on arrival, with a recommendation to awaken early on the day of the planned examination.
Patients aged 4yrs and above, with a diagnosis of ASD will be allocated and investigated for fulfillment of inclusion and exclusion criteria for study participation. The legal guardians of patients meeting study criteria will be approached for study participation consent. Patients declining consent will be treated with TFS as per current protocol. Patients for whom consent is attained will comprise the study group.
Study group patients will be randomized for treatment and stratified according to age groups: 4-7, 8-12, 12-18. Treatment will consist of 2 alternative pathways:
Oral Trichlofos Sodium (TFS) Pathway:
1. Initial Drug dose: Patients will be treated orally with 50mg/kg of TFS to maximum of 2000gr.
2. Failure to achieve sedate state 45 minutes after drug administration will enable an additional oral dose of 25mg/kg.
3. Patients failing to fall asleep following second drug dose will be regarded as treatment failure.
4. Rescue therapy according to physician's choice can be instituted (Dexmed or Neuleptil).
Intranasal Dexmedetomidine (IN DEX) Pathway:
1. Initial drug dose: Patients will be treated with IN 3mcg/kg of Dexmedetomidine to max dose of 150mcg. The drug will be delivered through MAD nasal atomizer.
2. Failure to achieve sedate state 45 minutes after drug administration will enable an additional dose of IN 1.5mcg/kg by MAD device.
3. Paitients failing to fall asleep following second drug dose will be regarded as treatment failure.
4. Rescue therapy according to physician's choice can be instituted (Neuleptil not recommended due to drug interactions).
All sedated children will be connected to monitoring including ECG chest leads in addition to oxygen pulse saturation monitoring.
Primary outcome assessment: Sedation depth by UMSS will be assessed by the EEG technician, who will be blinded to the drug used for sedation.
Secondary outcome assessment:
1. Satisfaction from sedation depth for completing exam by blinded technician on VAS score.
2. EEG motion artifact by interpreting neurologist, blinded to study drug on VAS score.
3. All other secondary outcomes from drug administration to discharge, including adverse events and needed interventions, will be documented by the nurse who is not blinded to administered drug.
4. ECG monitoring for determination of HR or arrhythmia
5. Assessing incidence of bradycardia, hypotension and their severity:
a. HR and BP age related normal value chart to be used as reference. b. Bradycardia and Hypotension determined in relation to lower normal value for age: i. Mild\<10% decrease from normal value ii. Moderate 10-20% decrease from normal value iii. Severe \>20% or signs of hemodynamic compromise
Ethics: This study is a comparison of two medications currently under routine use for performing sedated EEG's in our medical center. The study will be authorized by the Rabin Campus Helsinki Committee. Informed consent will be requested from the accompanying legal guardian.
Statistics: Based on our experience, we assume a 70% success rate for sedation using TFS and a 90% success rate for IN DEX. Using an alpha of 0.05 and 80% power, two groups of 62 patients would be needed, to demonstrate statistical significance.
This trial is planned as a pilot study aimed at assessing drug effects and recruitment rate, over a limited time period of up to 2 year, or up to 200 patiens (100 TFS + 100 IN DEX).
Randomization and age stratification: Patient allocation will be determined according to an age stratified randomization table. Patients will be stratified by 3 age groups: 4-7, 8-12, 12-18.
Funding: No funding has been allocated for this study. Study will be conducted using routine medications in current practice without additional cost.
Patients aged 4yrs and above, with a diagnosis of ASD will be allocated and investigated for fulfillment of inclusion and exclusion criteria for study participation. The legal guardians of patients meeting study criteria will be approached for study participation consent. Patients declining consent will be treated with TFS as per current protocol. Patients for whom consent is attained will comprise the study group.
Study group patients will be randomized for treatment and stratified according to age groups: 4-7, 8-12, 12-18. Treatment will consist of 2 alternative pathways:
Oral Trichlofos Sodium (TFS) Pathway:
1. Initial Drug dose: Patients will be treated orally with 50mg/kg of TFS to maximum of 2000gr.
2. Failure to achieve sedate state 45 minutes after drug administration will enable an additional oral dose of 25mg/kg.
3. Patients failing to fall asleep following second drug dose will be regarded as treatment failure.
4. Rescue therapy according to physician's choice can be instituted (Dexmed or Neuleptil).
Intranasal Dexmedetomidine (IN DEX) Pathway:
1. Initial drug dose: Patients will be treated with IN 3mcg/kg of Dexmedetomidine to max dose of 150mcg. The drug will be delivered through MAD nasal atomizer.
2. Failure to achieve sedate state 45 minutes after drug administration will enable an additional dose of IN 1.5mcg/kg by MAD device.
3. Paitients failing to fall asleep following second drug dose will be regarded as treatment failure.
4. Rescue therapy according to physician's choice can be instituted (Neuleptil not recommended due to drug interactions).
All sedated children will be connected to monitoring including ECG chest leads in addition to oxygen pulse saturation monitoring.
Primary outcome assessment: Sedation depth by UMSS will be assessed by the EEG technician, who will be blinded to the drug used for sedation.
Secondary outcome assessment:
1. Satisfaction from sedation depth for completing exam by blinded technician on VAS score.
2. EEG motion artifact by interpreting neurologist, blinded to study drug on VAS score.
3. All other secondary outcomes from drug administration to discharge, including adverse events and needed interventions, will be documented by the nurse who is not blinded to administered drug.
4. ECG monitoring for determination of HR or arrhythmia
5. Assessing incidence of bradycardia, hypotension and their severity:
a. HR and BP age related normal value chart to be used as reference. b. Bradycardia and Hypotension determined in relation to lower normal value for age: i. Mild\<10% decrease from normal value ii. Moderate 10-20% decrease from normal value iii. Severe \>20% or signs of hemodynamic compromise
Ethics: This study is a comparison of two medications currently under routine use for performing sedated EEG's in our medical center. The study will be authorized by the Rabin Campus Helsinki Committee. Informed consent will be requested from the accompanying legal guardian.
Statistics: Based on our experience, we assume a 70% success rate for sedation using TFS and a 90% success rate for IN DEX. Using an alpha of 0.05 and 80% power, two groups of 62 patients would be needed, to demonstrate statistical significance.
This trial is planned as a pilot study aimed at assessing drug effects and recruitment rate, over a limited time period of up to 2 year, or up to 200 patiens (100 TFS + 100 IN DEX).
Randomization and age stratification: Patient allocation will be determined according to an age stratified randomization table. Patients will be stratified by 3 age groups: 4-7, 8-12, 12-18.
Funding: No funding has been allocated for this study. Study will be conducted using routine medications in current practice without additional cost.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: